1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center


Stan Swartz, CEO,
The MD Health Channel

"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
"At 92...I had lost my will to live"
Tips on Aging
"Dr. Reyes gave me customized health care"

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
Runtime: 50:22
Runtime: 50:22
Runtime: 10:27
Runtime: 10:27
Runtime: 5:00
Runtime: 5:00
PDF Document 850 kb

Download Free

Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
Free Windows Media Player Click

Barrow Neurological Institute

October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  
December 2018  
January 2019  
February 2019  
March 2019  
April 2019  
May 2019  
June 2019  
July 2019  

This page is powered by Blogger. Isn't yours?

Friday, February 28, 2014


Cutting back on fry-ups 'reduces risk of dementia': Study finds compounds in bacon and eggs are linked with the disease Read more: http://www.dailymail.co.uk/health/article-2567097/Cutting-fry-ups-reduces-risk-dementia-Study-finds-compounds-bacon-eggs-linked-disease

A ‘compelling’ study has linked compounds found in fried meat and eggs with one of the hallmarks of Alzheimer’s disease.

Bacon is particularly problematic and the suspect chemicals are also found in many cakes, biscuits and pastries.


BP Meds Linked to Serious Fall Injuries in Elderly

Taking antihypertensive medications may lead to a significantly increased risk for serious fall injuries among older adults with hypertension and multiple comorbidities, according to an articlepublished online February 24 in JAMA Internal Medicine. The risk may be doubled for those individuals who have had a previous fall in the past year.

He continued, "For patients, it's not so simple. Most patients are on 10-plus medicines by the time they're 70, and it's been absolutely, unequivocally shown that when you're on 10-plus meds, the side effects start to creep up. If you fall, your morbidity goes skyrocketing. So anything you gain with blood pressure lowering starts to become eroded with what you lose with the blood pressure falling."

"What this article really brings forward, and it's not unique, is that the benefit of decreased cardiovascular events is completely integrated with the greater risk of falls," Daniel E. Forman, MD, chair of the American College of Cardiology Geriatric Cardiology Section, director of the exercise testing laboratory and cardiac rehabilitation at Brigham and Women's Hospital, and associate professor of medicine at Harvard Medical School in Boston, told Medscape Medical News in a telephone interview.
Read more »

Sunday, February 23, 2014


Study: Alzheimer's Risk Tied to Banned Pesticide

Exposure to the notorious pesticide DDT may play a role in development of Alzheimer's disease, a small case-control study suggested.
Levels of dichlorodiphenyldichloroethylene (DDE), the main metabolite of DDT, averaged 2.64 ng/mg in serum (SE 0.35) in 86 individuals diagnosed with Alzheimer's disease, compared with 0.69 ng/mg (SE 0.1) in 79 controls (P<0 .001="" span="">
Looked at another way, those study participants in the highest tertile of serum DDE level had quadruple the risk of carrying an Alzheimer's disease diagnosis (odds ratio 4.18, 95% CI 2.54-5.82 versus the lowest tertile), the researchers reported online in JAMA NeurologyMore

Friday, February 21, 2014


Anesthesia, Surgery Linked to a Doubling of Dementia Risk

Older patients who undergo anesthesia and surgery have a significantly increased risk for dementia, a large population-based study shows.

Investigators at Taipei Veterans General Hospital in Taiwan found that patients older than 50 years who underwent anesthesia for the first time had nearly a 2-fold increased risk for dementia, mainly Alzheimer's disease, compared with nonanesthetized patients.
"The results of our nationwide population-based study suggest that patients who undergo anesthesia and surgery may be at increased risk of developing dementia. Anesthesia and surgery are inseparable in clinical settings. Thus, it is difficult to establish whether the increased risk of dementia development we observed was attributable to the anesthesia per se, the surgical process, or both," principal investigator Jong-Ling Fuh, MD, said in a statement.
The study was published online July 25 in the British Journal of Psychiatry.
Although generally considered safe, there is growing concern that anesthetic drugs may have neurodegenerative complications.
Read more »

Tuesday, February 18, 2014


Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial

JAMA. 2014;311(7):682-691. doi:10.1001/jama.2014.93.
Text Size: A A A
Importance  Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.
Objective  The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability.
Design, Setting, and Participants  The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013.
Interventions  Participants (n = 186) were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability.
Main Outcomes and Measures  Primary outcome measures were based on scores from the 18-point Neurobehavioral Rating Scale agitation subscale (NBRS-A) and the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC). Other outcomes were based on scores from the Cohen-Mansfield Agitation Inventory (CMAI) and the Neuropsychiatric Inventory (NPI), ability to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on scores from the 30-point Mini Mental State Examination [MMSE]), and adverse events.
Results  Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures. The NBRS-A estimated treatment difference at week 9 (citalopram minus placebo) was −0.93 (95% CI, −1.80 to −0.06), P = .04. Results from the mADCS-CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P = .01. Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam. Worsening of cognition (−1.05 points; 95% CI, −1.97 to −0.13; P = .03) and QT interval prolongation (18.1 ms; 95% CI, 6.1-30.1; P = .01) were seen in the citalopram group.
Conclusions and Relevance  Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day.
Trial Registration  clinicaltrials.gov Identifier: NCT00898807
Neuropsychiatric symptoms occur in a majority of patients with Alzheimer disease. Agitation refers to emotional distress, excessive psychomotor activity, aggressive behaviors, disruptive irritability, and disinhibition. Agitation is common, persistent, difficult to treat, costly, and associated with severe adverse consequences for patients and caregivers.15 Psychological, environmental, and pharmacologic therapies have proven inadequate. Antipsychotic drugs continue to be widely used for agitation, despite serious safety concerns, including increased mortality, and uncertain efficacy.510
Citalopram, a selective serotonin reuptake inhibitor (SSRI) frequently used in older individuals,11,12 has been suggested as an alternative to antipsychotic drugs for agitation and aggression in dementia.1316 Yet there is limited evidence for its efficacy and safety. In a short-term unmasked study and 2 randomized, masked, follow-up studies, Pollock and colleagues1719 demonstrated the utility of citalopram for agitation in dementia, but these preliminary data require replication in a larger randomized, double-blind, placebo-controlled trial specific to an Alzheimer disease population.
The primary objective of the Citalopram for Agitation in Alzheimer Disease Study (CitAD) was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease and without major depression. The 3 secondary objectives were to: (1) examine the effects of citalopram on patients’ functional abilities and on caregiver distress; (2) examine the safety of citalopram (comparing between treatment groups) on vital signs, weight, gait stability, cognitive effects, electrolyte panels, adverse event reports, and electrocardiogram results (added later during the study); and (3) examine predictors of citalopram response. This article will address the primary objective and first 2 secondary objectives.


Age is the greatest single risk factor for developing dementia. When people reach age 65, their risk of dementia is 10%, and by age 85, approximately one-third will develop Alzheimer disease, the most common cause of dementia.

1 With 76 million US baby boomers entering or having entered this period of risk, a new wave of dementia cases can be anticipated—instead of today’s approximate 5 million people with dementia, nearly 14 million in the United States are expected to have dementia by 2050.2

First Page Preview

View Large
First page PDF preview

Monday, February 10, 2014


Anne Robbs, Editor, Anti-Aging Channel

Anne Robbs, Editor

Great benefit of wine!! 
Gotta read this...

"Resveratrol improves the health of mice on a high-fat diet and increases life span."

It was always postulated that resveratrol had benefits, but the question was proving the mechanisms involved and moving beyond the realm of "old wives tale" and into the science of the process.

Understanding how resveratrol works would move pharmacists forwards into the possibilities of an anti-aging drug, although most people would probably prefer to pop a cork rather than a bottle of pills, there are many diseases such as alzheimer's that could potentially be retarded with more focused treatment. It seems that mice lacking the longevity gene known as SIRT1, don't seem to show benefits from resveratrol.

Although its actions had in the past been attributed to its action on the SIRT1 gene, the naturally occurring molecule in red wine seems to have other effects on dozens of proteins and previous evidence had pointed researchers towards its effect on another gene known as AMPK. This research in mice, yeast, worms and flies, called into question the intelligence of creating an SIRT1 targeting drug, since resveratrol seemed to have other benefits. Due to these findings, Pharma company Sirtris halted its 2011 clinic trial of resveratrol.


The influence of aquariums on weight in individuals with dementia.

Placing a large fish tank in the dining area of extended-care facilities significantly increased appetite and weight gain in residents with severe dementia, who are at risk of excessive weight loss, according to a study in the current issue of Alzheimer Disease & Associated Disorders. Patients with advanced dementia are often given appetite-stimulating medications to maintain a healthy weight, but they can have serious side effects.

Residents in all three facilities increased their food consumption by approximately 6.9 ounces a day and gained an average of 2.2 pounds over the study period. The average weight of residents at the start of the study was 158.4 pounds and 160.6 pounds at the end. A weight loss of approximately 1.9 pounds was recorded in eight residents. The fish tanks had a calming effect, allowing residents to connect with nature and focus on eating, researchers said.

Read more »

Heavy alcohol consumption is associated with higher risk of vascular disease, which, in turn, may increase the risk of cognitive impairment

The study findings are in line with previous research and with accepted guidelines. According to Dr. Sabia, drinking fewer than 2-3 drinks a day for men and 1-2 drinks for women is "probably not deleterious" for cognitive outcomes. But these "safe limits" may be too high for older people because of the physiologic and metabolic changes related to aging, said Dr. Sabia. She pointed to recent evidence from a UK Royal College of Psychiatrists report (page 8) that suggests that the upper limit for those older than 65 years is 1.5 units per day or 11 units per week (1 unit = 8 grams). Some countries have specific consumption guidelines for the elderly. For example, said Dr. Sabia, the US National Institutes of Health (NIH) recommends that people older than 65 years not consume more than 7 drinks a week, and that they have no more than 3 drinks on any given day.
Read more »

Meditation in patients with mild cognitive impairment (MCI) may slow progression to Alzheimer's disease
"This study suggests that an intervention with meditation and yoga may impact the areas of the brain that are most susceptible to developing dementia," lead author Rebecca Erwin Wells, MD, MPH, who was at Beth Israel Deaconess Medical Center (BIDMC) at Harvard Medical School in Boston, Massachusetts, at the time of the study, told Medscape Medical News. Dr. Wells, who is now an assistant professor in the Department of Neurology at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, noted that although this was a small, preliminary study, she is "very excited" about the findings.
Read more »


Anne Robbs, News Editor, Anti-Aging Channel

Anne Robbs, Editor

A community-based fall prevention program effectively reduced the risk for falls among older adults, researchers said here.

The evidence-based program, called Step Up to Stop Falls, includes exercise, home assessment/modification, and community and/or healthcare provider education, according to Mary Gallant, PhD, MPH, at the University of Albany School of Public Health in Rensselaer, N.Y., and colleagues.

Exercise participants in the program saw significantly higher Timed-Up-and-Go (TUG) scores, Gallant reported at the American Public Health Association (APHA) annual meeting.

In addition, among those participants who had their homes inspected or modified, 60% resolved 100% of identified hazards, they added.

Finally, participants in the community educational programs demonstrated a significant increase in their belief that they could do things to reduce the risk of falls. Women were more likely than men to have actually done something in the past year to achieve that goal, the authors said.

Read more »


Alzheimer's Risk Tied to Banned Pesticide


Exposure to the notorious pesticide DDT may play a role in development of Alzheimer's disease, a small case-control study suggested...those study participants in the highest tertile of serum DDE level had quadruple the risk of carrying an Alzheimer's disease diagnosis (odds ratio 4.18, 95% CI 2.54-5.82 versus the lowest tertile), the researchers reported online in JAMA Neurology.

The researchers cited findings from recent federal surveys that found 75% to 80% of participants had measurable levels of DDE in serum. Other researchers not involved in the study cautioned that it was small, preliminary, and not designed to establish causality.

Huntington Potter, PhD, of the University of Colorado School of Medicine in Aurora, told MedPage Today that it was essentially "a pilot study." But Potter, as well as authors of an accompanying editorial in JAMA Neurology, noted that it was important for suggesting a specific environmental factor that may contribute to Alzheimer's disease risk -- something that has long been hypothesized but with few specific clues for where to look.

 "Richardson and colleagues have provided both a wake-up call to explore environmental influences and pointed us to a first area to assess -- pesticides, which have already been implicated in other human illnesses," wrote Steven DeKosky, MD, of the University of Virginia in Charlottesville, and Sam Gandy, MD, PhD, of the Mount Sinai Alzheimer's Disease Research Center in New York City, in the editorial.


Can a video game really diagnose Alzheimer's?
Akili Interactive Labs wants to try a different approach: The Boston-based startup recently signed a deal with Pfizer ($PFE) to see if its mobile video game platform can help diagnose early signs of Alzheimer's.  Akili plans to file the mobile app with the FDA, and, if approved, the game would be the first therapeutic app cleared in the U.S.

Vitamin E May Slow Functional Decline in Mild Alzheimer's

"Our study indicates that vitamin E could be recommended to improve functional outcomes, such as activities of daily living, for all levels of Alzheimer's disease starting with mild stages and gives good confidence that it is safe,"

The study, conducted at 14 Veterans Affairs medical centers, assessed the effect of vitamin E alone or with memantine on functional decline in 613 patients (97% men) with mild to moderate AD. At baseline, all of them were receiving an acetylcholinesterase inhibitor — most often donepezil (65%) and galantamine (32%).
By random assignment, 152 patients received 2000 IU of α-tocopherol per day, 155 received 20 mg of memantine per day, 154 received the combination of vitamin E and memantine, and 152 received placebo. They were followed for a mean of 2.3 years.



Anne Robbs, Editor, Anti-Aging Channel

Anne Robbs, Editor


"Virtual reality games can improve cognitive decline and
are better than traditional exercise"

There is research now claiming that virtual reality games can improve cognitive decline and are better than traditional exercise.   OK, ditch than exercise bike and invest in WII or PlayStation Move consoles with games like WII fit, bowling and cyber cycling.  These so-called “excergames” tend to increase the appeal of exercise by shifting away from some of the unpleasant aspects of working out and toward motivating features such as competition and 3-D scenery.  It’s fun while improving your body as well as you brain!

“We anticipated that seniors would enjoy cybercycling, which they did, but we did not anticipate such a robust and significant cognitive effect from cybercycling compared with traditional exercise,” lead investigator Cay Anderson-Hanley, PhD, from Union College, Schenectady, New York reported. “This gives us hope that more can be done to boost participation in exercise and increase the benefit of a workout through innovative excergames.”

Trials were completed on seniors and it showed that exercise can make a meaningful difference in brain health later in your life as well as yielding additional cognitive benefit.  In the study, older adults who cybercycled 2 to 3 times a week for 3 months had significantly greater cognitive benefit for the same effort as those who rode a traditional bike.  One explanation for the greater benefit found with cybercycling compared with traditional cycling is the added mental exercise required like navigating a 3-D landscape, anticipating turns and competing with others required additional focus, expanded divided attention and decision making.

Read more »